VivoSeq
Other

Tooth Disease

11

Pipeline Programs↗

0

Active Trials↗

5

Companies Involved↗

Tooth Disease is an emerging landscape with 11 programs across 5 companies. The most active players are GSK, CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., Boehringer Ingelheim. 5 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

0/100

Mech. Concentration

29/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

1 program

Phase 1C

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

1 program

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2N

Neurim Pharmaceuticals Ltd.

1 program

Phase 3K

Kenvue Brands

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Completed2 · 100%

Clinical Trials

Trial Activity

The Safety and Tolerability of CLZ-2002 in Patients With Charcot-Marie Tooth Disease.
Completed·—·Phase 1·NCT05947578·9 enrolled
Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease
Completed·UUniversity of Rochester·Phase 2·NCT02561702·4 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)